Insights
Insights From Our Experts
Articles
Expanding the Evidence: Real-World Insights into CDK4/6i Use in Elderly and BIPOC Patients with Metastatic Breast Cancer
Randomized controlled trials have long served as the foundation for establishing treatment efficacy, but they often fall short in representing the full diversity of patients seen in clinical practice. This is especially true in hormone receptor-positive/human…
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Patients today too often find themselves navigating a myriad of challenges that can make accessing quality healthcare a daunting task. Common obstacles range from financial barriers to long wait times to geographical and technological limitations and…
AI + RWE: Powering Smarter Patient Solutions
Artificial intelligence is transforming how we use real-world evidence (RWE) to improve patient care. As highlighted in Med Ad News’s online edition, pharmalive.com in the article, “AI backs up RWE”, machine learning is helping uncover patterns…
Reimagining Drug Safety: A New Era of Innovation
In a rapidly evolving healthcare landscape, the need for smarter, faster, and more scalable pharmacovigilance (PV) solutions has never been greater. In a recent interview with Pharmaceutical Executive, Vikram Anand shares how EVERSANA is meeting this challenge…
Unlocking the Future of Medical Information Analytics: A Q&A with Michael DeLuca of EVERSANA
EVERSANA’s recent collaboration with 3VUE is reshaping how medical information interactions and metrics are analyzed and visualized to demonstrate value and impact. We sat down with Michael DeLuca, Executive Vice President of Global Medical Affairs &…
Staying Ahead of the Curve in Pharmacovigilance: Mid-Year Pharmacovigilance Inspection Report 2025: Saudi Food & Drug Authority (SFDA)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The Saudi Arabia Drug Authority (SFDA) recently released its 2025 Mid-Year Pharmacovigilance Inspection Report,…
Staying Ahead of the Curve in Pharmacovigilance: Module VI Addendum II – Masking of Personal Data in Individual Case Safety (GVP)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The EMA and PRAC recently released the “Module VI Addendum II – Masking of…
Insights from BIO with OS Therapies
At this year’s BIO International Convention 2025, pharmaphorum’s Jonah Comstock sat down with Paul Romness, CEO of OS Therapies, and Farah Ahmad, VP of Business Development at EVERSANA, to explore how emerging biotech companies are navigating…
Case Study: Transforming Market Access with NAVLIN Insights KPI
How one global pharma team turned fragmented pricing data into strategic power. In a complex launch environment, pricing and market access teams face mounting pressure to deliver insights that resonate with CEOs, affiliates, payers, and investors.…
Pharmatizing AI & EVERSANA’s Bold Vision for Its AI Accelerator
EVERSANA continues to redefine the future of pharmaceutical commercialization with its newly launched AI Accelerator—a dedicated center of excellence designed to embed artificial intelligence across every touchpoint of the life sciences value chain. Spearheaded by Chief…